Another new CFO
18.09.2012 - German oncology expert Wilex AG has altered its executive management board. Dr. Jan Schmidt-Brand, who arrived from Wilex daughter Heidelberg Pharma, stepped into the CFO role at Wilex at the beginning of September.
Schmidt-Brandt was Managing Director at Heidelberg Pharma, which develops antibody-drug conjugates, until that firm was taken over by Wilex in November 2010. From 1997-2001, the trained lawyer was Managing Director of the Austrian BASF-Pharma subsidiary EBEWE Arznei-mittel GmbH, where his responsibilities included finance and controlling. Prior to that, he held several positions at the BASF Group over a period of eight years. In his final position there he was an executive in the chemical giant's central tax department. At the beginning of August, the firm announced that current CFO Peter Llewellyn-Davies would be stepping down when his six-year contract expired. Wilex announced that he is planning to pursue new activities, but will continue to act for the company in an advisory capacity.